Menu
Menu
Discover how Alamut™ Visual Plus helps you navigate variant interpretation evidence faster and with greater confidence in this clear, practical guide.
Adapted from Dr. Weei-Yuarn Huang’s (Sunnybrook Health Centre, Ontario, Canada) presentation during the webinar “Evaluating Next-Generation Sequencing Solutions for Real-World Clinical Needs in Myeloid Malignancy,” with permission from the author - This concordance study demonstrates the strong analytical performance of the new SOPHiA DDM™ Community Myeloid Solution and its potential to streamline and consolidate myeloid […]
Routine pharmacogenomic (PGx) testing has significant potential to improve drug efficacy and safety.
We’re often asked how we avoid overfitting when developing predictive machine learning models for clinical research. This technical note explains how.
Streamlined workflow for Chronic Lymphocytic Leukemia study
Learn how we addressed the unique challenges associated with genotyping mitochondrial DNA (mtDNA) to develop robust pipelines for mitochondrial genome analysis.
Read our descriptive guide to the HGVS nomenclature standard, genome reference assemblies, and MANE transcripts and how they are applied in Alamut™️ Visual Plus in this Technical Note.
Read our SOPHiA DDM™️ Dx ROS performance evaluation study and make confident data-driven decisions that improve patient care.
Check out our step-by-step guide to using SOPHiA DDM™️ complemented by Alamut™️ Visual Plus to streamline the interpretation of clinical exome data for neurological disorders.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.